In this episode, Dr. Shawn Tassone discusses the new FDA approval of a prescription called Addyi, aimed at treating Hypoactive Sexual Desire Disorder (HSDD) in women. He explains the differences between male and female sexual responses, the limitations of Addyi, and the marketing strategies that may mislead women about its effectiveness. Dr. Tassone emphasizes the importance of addressing underlying issues related to libido and the potential risks associated with Addyi, urging listeners to have open conversations with their partners and healthcare providers about sexual health. Episode Highlights: The history of Addyi How Addyi is marketed as a solution for women's sexual desire issues How the female sexual response is more complex than the male sexual response Factors that influence female libido beyond hormonal levels How Addyi affects serotonin levels similarly to antidepressants Why the marketing of Addyi may mislead women Results of clinical trials with Addyi What women should know about taking Addyi with other medications Why open communication with partners is crucial for women's sexual health Reasons underlying issues should be addressed before considering Addyi Episode Resources: Dr. Tassone's Free Women's Health Journal Club | Dr. T's Evidence Edit Dr. Shawn Tassone's Practice | Tassone Advanced Gynecology Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormonal Archetype Quiz Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related